VXRT News and Press, Vaxart Inc. From 02/24/22

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, ca...

Shares of Vaxart (NASDAQ:VXRT) are down 8% in premarket trading after releasing mid-stage data on its oral COVID-19 vaccine candidate. Results, published in BioRxiv and yet to be peer reviewed, found that the vaccine generated antibodies to the original COVID strain, as well as...

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’...

There's a strong argument against investing in speculative stocks, especially given the current state of the market. In recent weeks, investors have largely shifted away from these stocks due to perceived marketwide issues, most notably impending interest rate increases in the U.S. On t...

Recently, Flora Growth Corp. (NASDAQ:FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced the addition of Vessel founder and CEO, James Choe, to its executive team. “We are exci...

In the minds of many Americans, vaccines are practically synonymous with shots. However, one small company -- Vaxart (NASDAQ: VXRT) -- is developing an experimental oral COVID-19 vaccine. In this Motley Fool Live video, recorded on Jan. 19 , Fool contributors Keith Spei...

If you could immunize yourself against COVID-19 from the comfort of your home by just taking a pill, I'm guessing you'd prefer that approach to getting poked in the arm at a clinic. And that's what makes Vaxart (NASDAQ: VXRT) a compelling company, not to mention a potentially killer...

The recent surge in COVID-19 cases caused by the new and more contagious omicron variant of the coronavirus has taught us at least one thing: There's still a dire need for effective vaccines against this potentially deadly disease. Here's why this matters for investors. Several companie...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart  (NASDAQ: VXRT ) is a clinical-stage biotech company focused on commercializing orally-delivered vaccines. VXRT stock has been volatile in 2021, thanks to hopes and setbacks related to its potential Covid-1...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virt...